QQ客服 官方微博 反馈留言

	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
	Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng
刊名	LANCET ONCOLOGY
	2015
卷号	16期号:2
ISSN号	1470-2045
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3436965
专题	昆明医科大学
推荐引用方式 GB/T 7714	Yang, James Chih-Hsin,Wu, Yi-Long,Schuler, Martin,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials[J]. LANCET ONCOLOGY,2015,16(2).
APA	Yang, James Chih-Hsin.,Wu, Yi-Long.,Schuler, Martin.,Sebastian, Martin.,Popat, Sanjay.,...&Sequist, Lecia V..(2015).Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.LANCET ONCOLOGY,16(2).
MLA	Yang, James Chih-Hsin,et al."Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials".LANCET ONCOLOGY 16.2(2015).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。